ASPHO Clinical Video Series
Microlearning for On-the-Go PHO Specialists
Fit learning into your busy day with the just-in-time Clinical Video Series featuring microlearning video segments for today’s on-the-go specialist. Gain the education tools you need in convenient, easy-to-access 15-20 minute visual lessons accompanied by narration and tutorials from experts in their fields. The video series features four segments each on Hematology/Anticoagulants and Oncology/Immunotherapy, with each lesson diving into standards of care, difficult or unique cases, emerging technologies, new research, and innovative therapies. Up to 2 AMA PRA Category 1 Credits™ available.
Hematology Set:
Anticoagulants - Pediatric Venous Thromboembolism (VTE)
- Treatment Duration for Pediatric VTE
- Learning Objectives:
- Review current literature recommendations regarding when to treat for pediatric VTE.
- Identify the appropriate treatment duration for pediatric VTE.
- Apply evidence-based guidelines to determine treatment recommendations for patients with symptomatic CVL-related thrombosis, asymptomatic CVL-related thrombosis, and unprovoked thrombosis.
- Learning Objectives:
- Direct Oral Anticoagulants (DOACs)
- Learning Objectives:
- List and describe the most commonly used DOACs.
- Review published data from pediatric DOAC clinical trials.
- Indicate practice considerations when prescribing DOACs, including dosing, laboratory monitoring, and managing bleeding.
- Learning Objectives:
- Preventing and Treating VTE in Pediatric Cancer Patients
- Learning Objectives:
- Understand risk factors for VTE in the setting of pediatric cancer patients.
- Identify prevention strategies for VTE in pediatric cancer patients.
- Determine management strategies for VTE in pediatric cancer patients.
- Learning Objectives:
- Prevention of Hospital-Acquired Pediatric VTE
- Learning Objectives:
- Review the epidemiology of hospital acquired pediatric VTE.
- Identify prevention strategies for hospital acquired pediatric VTE.
- Understand pediatric VTE complications in post-surgical patients and patients with COVID-19, determining indications for thromboprophylaxis.
- Learning Objectives:
Speaker
Sarah O’Brien, MD MSc
Nationwide Children's Hospital
Columbus, OH
Oncology Set:
Immunotherapies for Pediatric Cancer
- Immunotherapy for Hodgkin Lymphoma
- Speaker: Peter Cole, MD
- Learning Objectives:
- Understand the history and background of immunotherapy.
- Review the mechanisms of action and clinical trial data related to Antibody-Drug Conjugates and Checkpoint inhibitors for pediatric patients with relapsed or refractory Hodgkin lymphoma.
- Identify the immunotherapeutic strategies of combining conventional chemotherapy with other immunotherapies.
- Learning Objectives:
- Speaker: Peter Cole, MD
- Acute Leukemia: BiTE Antibodies in Childhood Cancer
- Speaker: Lia Gore, MD
- Learning Objectives:
- Understand the background and mechanisms of use for BiTEs in the context of immunotherapies for childhood cancers.
- Review clinical trial information regarding current use of cancer antigens and BiTEs for childhood ALL.
- Identify current considerations, implications, and best practices with using BiTEs to treat childhood cancer patients.
- Learning Objectives:
- Speaker: Lia Gore, MD
- Acute Leukemia: Immunotoxins and Antibody Drug Conjugates (ADCs)
- Speaker: Lia Gore, MD
- Learning Objectives:
- Understand the background and mechanisms of use for Antibody-Drug Conjugates (ADCs) in the context of cancer therapy.
- Review the current literature supporting the evolution and use of immunotherapies and ADCs for ALL and childhood hematologic malignancies.
- Describe clinical trial developments and identify the challenges associated with using ADCs to treat childhood cancer patients.
- Learning Objectives:
- Speaker: Lia Gore, MD
- CAR-T Cell Therapy
- Speaker: Shannon Maude, MD PhD
- Learning Objectives:
- Understand the design, structure, function, and mechanism of CAR T-Cell immunotherapy in the context of cancer therapy.
- Review the current literature supporting the use of CAR- T Cell therapy for ALL in childhood cancer patients.
- Describe clinical trial developments and identify the challenges and potential expanded use of CAR-T Cell therapy to treat childhood cancer patients.
- Learning Objectives:
- Speaker: Shannon Maude, MD PhD
Speakers
Peter Cole, MD
Rutgers Cancer Institute of New Jersey
Lia Gore, MD
University of Colorado School of Medicine
Children’s Hospital Colorado
Shannon Maude, MD PhD
Children’s Hospital of Philadelphia
The University of Pennsylvania School of Medicine
Pricing:
The Clinical Video Series is available in a variety of convenient and customizable purchase options. Plus, members receive exclusive savings! Not a member? Learn more about joining ASPHO.
Learners can purchase the Hematology and Oncology Sets together as a discounted bundle and access even more learning.
Full Series (includes both the Hematology and Oncology Sets)
- Member: $170
- Trainee Member: $85
- Non-member: $270
Not interested in the full series? The Hematology and Oncology Sets are available individually or for single episode purchases.
Single Set (Hematology Set or Oncology Set)
- Member: $99
- Trainee Member: $50
- Non-member: $160
Single Episodes
- Member: $30
- Trainee Member: $15
- Non-member: $50
Purchase single episodes using the links below:
- Treatment Duration for Pediatric VTE
- Direct Oral Anticoagulants
- Preventing and Treating VTE in Pediatric Cancer Patients
- Prevention of Hospital-Acquired Pediatric VTE
- Immunotherapy for Hodgkin Lymphoma
- Acute Leukemia: BiTE Antibodies in Childhood Cancer
- Acute Leukemia: Immunotoxins and Antibody Drug Conjugates (ADCs)
- CAR-T Cell Therapy
Continuing Medical Education Credit
The American Society of Pediatric Hematology/Oncology (ASPHO) offers continuing medical education (CME) credit for sessions viewed and evaluated. A certificate will be issued upon receipt of the evaluation. ASPHO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
ASPHO designates this activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ASPHO requires all planners, faculty (presenters and moderators), reviewers, and any others involved in the development of CME content to disclose all financial relationships they have with ineligible companies in the last 24 months. Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ASPHO also requires disclosure of the intent to discuss unlabeled or investigational use(s) of a commercial product or investigational use of a product not yet approved for this purpose. The ASPHO Accreditation Subcommittee reviews all financial relationships as submitted in the disclosure form by planners and presenters and mitigates such conflicts to ensure the content of the activity is aligned with the interests of the public.
To view the 2021 Clinical Video Series speaker, planner, and reviewer disclosures, click here.
Disclaimer
The material presented in this activity represents the opinion of the speakers and not necessarily the views of ASPHO.
Evaluation
To access the evaluation, log into your My Library with your ASPHO username and password. Click on the graduation cap next to “Clinical Video Series” for each episode.
0.25 CME hour is available for each episode (up to 1.0 CME hour for each series, and up to 2.0 CME hours total for both series).